Multaq and Eosinophilia - a phase IV clinical study of FDA data

Summary:

Eosinophilia is reported as a side effect among people who take Multaq (dronedarone hydrochloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Corgard, and have Mantle cell lymphoma.

The phase IV clinical study analyzes which people have Eosinophilia when taking Multaq. It is created by eHealthMe based on reports of 10,572 people who have side effects when taking Multaq from the FDA, and is updated regularly.

What is Multaq?

Multaq has active ingredients of dronedarone hydrochloride. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 11,053 Multaq users. Check the latest studies of Multaq.

What is Eosinophilia?

Eosinophilia (eosinophil count in the peripheral blood exceeds) is found to be associated with 957 drugs and 1,392 conditions by eHealthMe. Check the latest studies of Eosinophilia.

On Jul, 08, 2026

10,572 people reported to have side effects when taking Multaq.
Among them, 12 people (0.11%) have Eosinophilia.

Among these 12 people:

How long have people been on Multaq when they have Eosinophilia? *

What is the gender of people who have Eosinophilia when taking Multaq? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Eosinophilia when taking Multaq? *

What are other drugs people take besides Multaq? *

What are other side effects people have besides Eosinophilia? *

Dyspnea (difficult or laboured breathing): 6 people, 50.00%
Interstitial Lung Disease: 6 people, 50.00%
Enanthema (rash formed inside the body): 2 people, 16.67%
Transaminases Increased: 2 people, 16.67%
International Normalised Ratio Increased: 2 people, 16.67%
Fever: 2 people, 16.67%
Neutrophilia: 2 people, 16.67%
Fatigue (feeling of tiredness): 2 people, 16.67%
Abdominal Pain Upper: 2 people, 16.67%
Drug-Induced Liver Injury (diseases of the liver that are caused by physician-prescribed medications): 2 people, 16.67%

What are the existing conditions these people have? *

Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 1 person, 8.33%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 8.33%
Pain: 1 person, 8.33%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Multaq and have Eosinophilia?

- Check whether Eosinophilia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Multaq:

Multaq (11,053 reports)

Eosinophilia treatments and more:

Eosinophilia (20,276 reports)

Browse all side effects of Multaq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Eosinophilia:

Eosinophilia (957 drugs)

Browse all the conditions that are associated with Eosinophilia:

Eosinophilia (1,392 conditions)

Related publications that referenced our studies

Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Guidelli GM, Tenti S, Fioravanti A, "Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis", Indian Journal of Dermatology, Venereology, and Leprology, 2015 Jan .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
Guidelli GM, Tenti S, Fioravanti A, "Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis", Indian Journal of Dermatology, Venereology, and Leprology, 2015 Jan .
Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on dronedarone hydrochloride (the active ingredients of Multaq) and Multaq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.